In the past decade, advances in the use of monoclonal antibodies (mAbs) and adoptive
cellular therapy to treat cancer by modulating the immune response have led to …

Successes of immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cell
therapy in curing patients with otherwise lethal cancers have validated immunotherapy as a …

Cancer treatments often reach a refractory period leading to treatment failure and patients
developing disease recurrence. This can be due to tumour cells escaping the immune …

The results of recent clinical trials using novel immunotherapy strategies such as immune
checkpoint blockade and adoptive T-cell therapy approaches including CAR T-cell therapy …

In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-
T) therapy are two milestone achievements in clinical immunotherapy. However, both show …

After decades of setbacks, cancer immunology is living its Golden Age. Recent advances in
cancer immunology have provided new therapeutic approaches to treat cancer. The …

The development of novel targeted therapies with acceptable safety profiles is critical to
successful cancer outcomes with better survival rates. Immunotherapy offers promising …

For many cancer types, the immune system plays an essential role in their development and
growth. Based on these rather novel insights, immunotherapeutic strategies have been …

Chimeric antigen receptor (CAR) T cell therapy represents the first US Food and Drug
Administration approved gene therapy and these engineered cells function with …

With the advent of cancer immunotherapy, there has been a major improvement in patient's
quality of life and survival. The growth of cancer immunotherapy has dramatically changed …